A5047113235- Protein Degradation and Inhibitors
- Histone Deacetylase Inhibitors Research
- CAR-T cell therapy research
- Click Chemistry and Applications
- Chromatin Remodeling and Cancer
- Epigenetics and DNA Methylation
- Acute Lymphoblastic Leukemia research
- Histiocytic Disorders and Treatments
- Mast cells and histamine
- Fibroblast Growth Factor Research
- Cancer Genomics and Diagnostics
- Cancer Research and Treatments
- Immune Cell Function and Interaction
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Acute Myeloid Leukemia Research
- Lipid Membrane Structure and Behavior
- Ubiquitin and proteasome pathways
- Neonatal and fetal brain pathology
- Cancer, Hypoxia, and Metabolism
Royal College of Surgeons in Ireland
2018-2021
Discovery of a new HDAC6 inhibitor reveals role for in the regulation glycolytic metabolism.
Recent studies suggest that even mild hypoxia-induced neonatal seizures can trigger an acute neuroinflammatory response leading to long-lasting changes brain excitability and associated cognitive behavioral deficits. The cellular elements signaling pathways underlying neuroinflammation in this setting remain incompletely understood but could yield novel therapeutic targets. Here we show brief global mice result short-lasting cytokine production as well selective expansion of the microglia...
Abstract B-cell lymphoma 2 (BCL-2) has recently emerged as a therapeutic target for early T-cell progenitor acute lymphoblastic leukemia (ETP-ALL), high-risk subtype of human ALL. The major clinical challenge with targeted therapeutics, such the BCL-2 inhibitor ABT-199, is development acquired resistance. We assessed in vivo response luciferase-positive LOUCY cells to ABT-199 monotherapy and observed specific residual disease splenic microenvironment. Of note, these results were confirmed by...
Invasive lobular carcinoma (ILC) is a subtype of breast cancer accounting for 10% tumors. The majority patients are treated with endocrine therapy; however, resistance common in estrogen receptor-positive and new therapeutic strategies needed. Bromodomain extraterminal inhibitors (BETi) effective diverse types but they have not yet been assessed ILC.
Introduction T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive hematologic malignancy resulting from the transformation of progenitors. Early progenitor ALL (ETP-ALL) subgroup accounts for 5% to 10% T-ALL cases and associated with a poor prognosis very high risk relapse. leukemias develop dependence on anti-apoptotic BCL-2 family proteins that linked maturation stage blasts. Typical mostly dependent BCL-XL, whereas ETP-ALL more BCL-2. In recent years, there has been development...
<p>Table S2: Primer List</p>
<p>Figure S4. Induction of FGFR1 following JQ1 treatment in ILC and IDC cell lines.</p>
<p>Figure S1. Characterization of MM134, SUM44, CAMA-1 and OCUB-M ILC cell lines.</p>
<p>supplementary data figure legends updated to include wnt11 knockdown in FigS3 (untracked)</p>
<p>Figure S6. BRD3 and BRD4 are associated with disease-specific survival in METABRIC cohort.</p>
<p>Table S4: Multivariate analysis on RATHER RNA-seq data</p>
<p>Figure S5: FGFR1 and JQ1 combination in 3D cultures of CAMA1 IDC cell lines</p>
<p>Table S1. Patient data from the RATHER primary ILC cohort</p>
<p>Table S3: Cox regression analysis on RATHER RNA-seq data</p>
<p>Updated FigS3 to include wnt11 knockdown data</p>
<p>Figure S2. JQ1 in combination with 1ï�M ABT-199 does not show synergy ILC cell lines 2D culture.</p>
<p>Table S1. Patient data from the RATHER primary ILC cohort</p>
<p>supplementary data figure legends updated to include wnt11 knockdown in FigS3 (untracked)</p>
<p>Figure S5: FGFR1 and JQ1 combination in 3D cultures of CAMA1 IDC cell lines</p>
<p>Updated FigS3 to include wnt11 knockdown data</p>
<p>Table S3: Cox regression analysis on RATHER RNA-seq data</p>
<p>Figure S2. JQ1 in combination with 1ï�M ABT-199 does not show synergy ILC cell lines 2D culture.</p>
<p>Figure S1. Characterization of MM134, SUM44, CAMA-1 and OCUB-M ILC cell lines.</p>
<p>Table S2: Primer List</p>
<p>Figure S6. BRD3 and BRD4 are associated with disease-specific survival in METABRIC cohort.</p>